of three novel product platform companies in the NLV portfolio are Pearl Therapeutics (NLV-I, private, pulmonology, exited at 2.5x plus milestones), Epizyme (NLV-II, NASDAQ: EPZM, oncology, exited at 2.0x), and Principia (NLV-IL private, immunology & oncology). e Later development stage and commercial st